Outcomes of etonogestrel subdermal contraceptive implants

References

1. 1.↵
   1. N. V. Organon

   . NEXPLANON^® and IMPLANON^® (etonogestrel implant). [Updated 2011; accessed date?]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021529s011lbl.pdf
2. 2.↵
   1. Maddox DD,
   2. Rahman Z

   . Etonogestrel (Implanon), another treatment option for contraception. P T 2008 Jun;33: 337-347.

   OpenUrl
3. 3.↵
   1. Moray KV,
   2. Chaurasia H,
   3. Sachin O,
   4. Joshi B.

   A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health 2021; 18: 4.

   OpenUrlCrossRef
4. 4.↵
   1. Bahamondes L,
   2. Brache V,
   3. Meirik O,
   4. Ali M,
   5. Habib N,
   6. Landoulsi S.

   A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod 2015; 30: 2527-2538.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Aisien AO,
   2. Enosolease ME. Safety

   , efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract 2010; 13: 331-335.

   OpenUrlPubMed
6. 6.
   1. Apter D,
   2. Briggs P,
   3. Tuppurainen M,
   4. Grunert J,
   5. Lukkari-Lax E,
   6. Rybowski S,et al.

   A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril 2016; 106: 151-157.

   OpenUrl
7. 7.↵
   1. Yildizbas B,
   2. Sahin HG,
   3. Kolusari A,
   4. Zeteroglu S,
   5. Kamaci M.

   Side effects and acceptability of Implanon: a pilot study carried out in eastern Turkey. Eur J Contracept Reprod Health Care 2007; 12: 248-252.

   OpenUrlPubMed
8. 8.↵
   1. Bitzer J,
   2. Tschudin S,
   3. Alder J.

   Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004; 9: 278-284.

   OpenUrlPubMed
9. 9.↵
   1. Hidalgo MM,
   2. Lisondo C,
   3. Juliato CT,
   4. Espejo-Arce X,
   5. Monteiro I,
   6. Bahamondes L.

   Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception 2006; 73: 532-536.

   OpenUrlPubMed
10. 10.↵
    1. Mamecha Mesha,
    2. Akalewold Alemayehu,
    3. Deresse Daka

    . Prevalence and factors associated with early discontinuation rate of Implanon utilization among women who ever used Implanon in Kucha District Gamo Gofa Zone, Southern Ethiopia. BMC Womens Health 2020; 20: 239.

    OpenUrl
11. 11.↵
    1. Gezginc K,
    2. Balci O,
    3. Karatayli R,
    4. Colakoglu MC.

    Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care 2007; 12: 362-365.

    OpenUrlPubMed
12. 12.↵
    1. Thamkhantho M,
    2. Jivasak-Apimas S,
    3. Angsuwathana S,
    4. Chiravacharadej G,
    5. Intawong J.

    One-year assessment of women receiving sub-dermal contraceptive implant at Siriraj Family Planning Clinic. J Med Assoc Thai 2008; 91: 775-780.

    OpenUrlPubMed
13. 13.↵
    1. Gupta S,
    2. Mola G,
    3. Ramsay P,
    4. Jenkins G,
    5. Stein W,
    6. Bolnga J, et al.

    Twelve month follow-up of a contraceptive implant outreach service in rural Papua New Guinea. Aust N Z J Obstet Gynaecol 2017; 57: 213-218.

    OpenUrlPubMed
14. 14.↵
    1. Ismail H,
    2. Mansour D,
    3. Singh M.

    Migration of Implanon. J Fam Plann Reprod Health Care 2006; 32: 157-159.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Carlos-Alves M,
    2. Gomes M,
    3. Abreu R,
    4. Pinheiro P.

    Lung migration of contraceptive Implanon NXT. BMJ Case Rep 2019; 12: e230987.

    OpenUrl
16. 16.
    1. Cerato A,
    2. Luyckx M,
    3. Ghaye B.

    Migration of Implanon contraceptive implant into the pulmonary artery. Diagn Interv Imaging 2019; 100: 59-60.

    OpenUrl
17. 17.↵
    1. Park JU,
    2. Bae HS,
    3. Lee SM,
    4. Bae J,
    5. Park JW.

    Removal of a subdermal contraceptive implant (Implanon NXT) that migrated to the axilla by C-arm guidance: a case report and review of the literature. Medicine (Baltimore) 2017; 96: e8627.

    OpenUrl
18. 18.↵
    1. Winner B,
    2. Peipert JF,
    3. Zhao Q,
    4. Buckel C,
    5. Madden T,
    6. Allsworth JE, et al.

    Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366: 1998-2007.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Harrison-Woolrych M,
    2. Hill R.

    Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005; 71: 306-308.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Romano ME,
    2. Braun-Courville DK.

    Assessing weight status in adolescent and young adult users of the etonogestrel contraceptive implant. J Pediatr Adolesc Gynecol 2019; 32: 409-414.

    OpenUrlCrossRef
21. 21.↵
    1. Modesto W,
    2. Dal Ava N,
    3. Monteiro I,
    4. Bahamondes L.

    Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet 2015; 292: 1387-1391.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Vickery Z,
    2. Madden T,
    3. Zhao Q,
    4. Secura GM,
    5. Allsworth JE,
    6. Peipert JF.

    Weight change at 12 months in users of 3 progestin-only contraceptive methods. Contraception 2013; 88: 503-508.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Tesfaye H,
    2. Negara E,
    3. Bayisa K.

    Early implanon discontinuation and associated factors among women ever used Implanon in Mettu district, Oromia regional state, southwest Ethiopia, 2021. Reprod Health 2021; 18: 176.

    OpenUrl
24. 24.↵
    1. Casey PM,
    2. Long ME,
    3. Marnach ML,
    4. Bury JE.

    Bleeding related to etonogestrel subdermal implant in a US population. Contraception 2011; 83: 426-430.

    OpenUrlCrossRefPubMed